Candriam S.C.A. Grows Position in Moderna, Inc. (NASDAQ:MRNA)

Candriam S.C.A. raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 9.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 482,052 shares of the company's stock after buying an additional 40,007 shares during the quarter. Candriam S.C.A. owned about 0.13% of Moderna worth $57,241,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Quadrant Capital Group LLC increased its holdings in Moderna by 7.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company's stock valued at $266,000 after purchasing an additional 187 shares during the period. Ontario Teachers Pension Plan Board purchased a new position in Moderna during the 4th quarter valued at about $1,358,000. Hobbs Group Advisors LLC purchased a new position in Moderna during the 4th quarter valued at about $664,000. Illinois Municipal Retirement Fund increased its holdings in Moderna by 22.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company's stock valued at $5,519,000 after purchasing an additional 9,360 shares during the period. Finally, Swedbank AB purchased a new position in Moderna during the 1st quarter valued at about $3,315,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Royal Bank of Canada downgraded Moderna from an "outperform" rating to a "sector perform" rating and reduced their target price for the stock from $125.00 to $90.00 in a report on Monday, August 5th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a "sell" rating to a "hold" rating and reduced their target price for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. HSBC upgraded Moderna from a "reduce" rating to a "hold" rating and set a $82.00 target price on the stock in a report on Wednesday, August 28th. William Blair reiterated a "market perform" rating on shares of Moderna in a report on Thursday, June 27th. Finally, Hsbc Global Res upgraded Moderna from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 28th. Ten research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $123.79.

Moderna Stock Down 0.7 %

MRNA stock traded down $0.55 during midday trading on Friday, hitting $72.89. The company's stock had a trading volume of 3,425,366 shares, compared to its average volume of 4,078,099. The company has a market cap of $27.93 billion, a PE ratio of -4.65 and a beta of 1.67. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The firm's 50-day moving average is $99.26 and its 200-day moving average is $112.31.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company's revenue for the quarter was down 29.9% on a year-over-year basis. During the same period last year, the business posted ($3.62) EPS. On average, equities research analysts forecast that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the firm's stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CFO James M. Mock sold 1,321 shares of the firm's stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction on Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the transaction, the president now owns 1,457,089 shares in the company, valued at $201,311,416.24. The disclosure for this sale can be found here. Insiders have sold a total of 316,168 shares of company stock worth $44,094,621 in the last ninety days. Insiders own 15.70% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.